Shared more. Cited more. Safe forever.
    • advanced search
    • submit works
    • about
    • help
    • contact us
    • login
    View Item 
    •   MOspace Home
    • University of Missouri-Columbia
    • School of Medicine (MU)
    • Department of Medicine (MU)
    • Division of Hospital Medicine (MU)
    • 2017-present: American journal of hospital medicine
    • American journal of hospital medicine, volume 1, issue 4 (2017 October-December)
    • View Item
    •   MOspace Home
    • University of Missouri-Columbia
    • School of Medicine (MU)
    • Department of Medicine (MU)
    • Division of Hospital Medicine (MU)
    • 2017-present: American journal of hospital medicine
    • American journal of hospital medicine, volume 1, issue 4 (2017 October-December)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    advanced searchsubmit worksabouthelpcontact us

    Browse

    All of MOspaceCommunities & CollectionsDate IssuedAuthorAuthor/ContributorTitleSubjectIdentifierThesis DepartmentThesis AdvisorThesis SemesterThis CollectionDate IssuedAuthorAuthor/ContributorTitleSubjectIdentifierThesis DepartmentThesis AdvisorThesis Semester

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular AuthorsStatistics by Referrer

    Review Article : Sacubitril/valsartan use for the hospitalist

    Padkins, Mitchell
    Hart, James
    Littrell, Rachel
    View/Open
    [PDF] AmericanJournalOfHospitalMedicine2017V1I4Padkins.pdf (226.6Kb)
    Date
    2017-10
    Format
    Article
    Metadata
    [+] Show full item record
    Abstract
    The mainstays of therapy for heart failure with reduced ejection fraction (HFrEF) have traditionally been angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), beta-blockers, aldosterone receptor antagonists, and diuretics for symptomatic relief (1). With few advances made over the past few decades, the principles of treating HFrEF have been revolutionized following the results of the PARADIGM-HF trial (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure) in 2014. The trial compared the novel agent sacubitril/valsartan (Entresto(R)) to Enalapril (1). Sacubitril/valsartan is a combination angiotensin II receptor blocker-neprilysin inhibitor (ARNI) that replaces traditional ACEI and ARB therapy in the treatment of HFrEF. The PARADIGM-HF trial was stopped early due to overwhelming evidence of decreased mortality and decreased HFrEF related hospitalizations with sacubitril/valsartan when compared to Enalapril (2). Since the study was released, the American College of Cardiology (ACC), the American Heart Association (AHA), and the Heart Failure Society of America (HFSA) released updated guidelines in May 2016. Sacubitril/valsartan now holds a Class I Recommendation for the treatment of HFrEF in patients with New York Heart Association (NYHA) class II or III heart failure (3). These recommendations were further upheld in the recently released 2017 ACC/AHA/HFSA Focused Update for the Management of Heart Failure (4).
    URI
    https://hdl.handle.net/10355/63350
    Part of
    Review Article
    Part of
    American journal of hospital medicine, volume 1, issue 4 (2017 October-December)
    Citation
    Am J Hosp Med 2017 Oct;1(4):2017.029 https://doi.org/10.24150/ajhm/2017.029
    Collections
    • American journal of hospital medicine, volume 1, issue 4 (2017 October-December)

    Send Feedback
    hosted by University of Missouri Library Systems
     

     


    Send Feedback
    hosted by University of Missouri Library Systems